"The US Food and Drug Administration (FDA) approved daclizumab (Zinbryta, Biogen Idec) today for treatment of patients with relapsing forms of multiple sclerosis (MS), according to an FDA news release.
The agency cautions, how"...
REBIF is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/3/2016
Additional Rebif Information
Rebif - User Reviews
Rebif User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.